LegisTrack
Back to all bills
S 1305119th CongressIn Committee

Agility in Manufacturing Preparedness Act of 2025

Introduced: Apr 4, 2025
Standard Summary
Comprehensive overview in 1-2 paragraphs

The Agility in Manufacturing Preparedness Act of 2025, introduced by Senators Tillis and Coons, would expand BARDA’s (Biomedical Advanced Research and Development Authority) strategic initiatives to explicitly include manufacturing technologies and platforms. It authorizes strategic coordination between BARDA and the Manufacturing USA network (a group of federal manufacturing innovation institutes established under the NIST Act) to pursue biomanufacturing missions. The goal is to develop, demonstrate, and deploy manufacturing technologies and response capabilities to strengthen public health and medical preparedness, thereby increasing domestic biomanufacturing capacity and accelerating the ability to respond to health emergencies. In short, the bill creates a formal pathway for closer collaboration between BARDA and the Manufacturing USA institutes to advance biomanufacturing innovation as a core component of national health security.

Key Points

  • 1Expands BARDA’s scope by adding “manufacturing technologies” and “platforms” to its list of strategic initiatives related to countermeasures.
  • 2Authorizes strategic coordination between BARDA and the Manufacturing USA network in biomanufacturing missions.
  • 3Directs collaboration toward developing, demonstrating, and deploying technologies and response capabilities to improve public health and medical preparedness.
  • 4Specifies that the Manufacturing USA network is the group established under section 34 of the National Institute of Standards and Technology Act.
  • 5Introduced in the Senate in 2025 by Senators Tillis (along with Senator Coons) and referred to the Health, Education, Labor, and Pensions Committee; the bill is in an early, introductory stage.

Impact Areas

Primary group/area affected: BARDA, the Manufacturing USA institutes, and the broader biomanufacturing ecosystem within the United States.Secondary group/area affected: Public health agencies and manufacturers involved in emergency preparedness, vaccine and therapeutic production, and related supply chains.Additional impacts: Potential acceleration of domestic manufacturing capabilities for health emergencies, enhanced interagency collaboration, and the development and deployment of new biomanufacturing technologies and platforms.
Generated by gpt-5-nano on Nov 18, 2025